Skip Nav Destination
Issues
February 2018
ISSN 2296-5270
EISSN 2296-5262
Journal Name Change
Vol. 1-36 (1978-2013) were published under the journal's former title Onkologie.
Oncology Research and Treatment 2018, Vol. 41, No. 1-2
Editorial Board / Contents / Imprint
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 1–7.
https://doi.org/10.1159/000486873
Research Article
Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series
Subject Area:
Oncology
Raffaella Palumbo; Luca Licata; Federico Sottotetti; Barbara Tagliaferri; Emma Pozzi; Cristina Teragni; Erica Quaquarini; Antonio Bernardo
Oncol Res Treat (2018) 41 (1-2): 8–13.
https://doi.org/10.1159/000481098
Association between IL-13 Gene rs20541 Polymorphism and Glioma Susceptibility: A Meta-Analysis
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 14–21.
https://doi.org/10.1159/000480518
Percutaneous Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction Caused by Recurrence and Metastasis after Primary Tumor Resection
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 22–28.
https://doi.org/10.1159/000481096
Is Surgical Excision Necessary in Breast Papillomas 10 mm or Smaller at Core Biopsy
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 29–34.
https://doi.org/10.1159/000481097
Rigid Triple Endoscopy Improves Clinical Staging of Primary Head and Neck Cancer
Subject Area:
Oncology
Shachi J. Sharma; Jens J. Linke; Tobias Kroll; Nora Wuerdemann; Jens P. Klussmann; Orlando Guntinas-Lichius; Claus Wittekindt
Oncol Res Treat (2018) 41 (1-2): 35–38.
https://doi.org/10.1159/000481173
Comparing a Right- Versus Left-Side Approach in Laparoscopy-Assisted D2 Radical Gastrectomies in Overweight Patients with Gastric Cancer: A Retrospective Case-Controlled Study
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 39–46.
https://doi.org/10.1159/000481259
Review Article
Prognostic Value of miR-375 for Survival Outcomes in Various Cancers: A Systematic Review and Meta-Analysis
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 47–50.
https://doi.org/10.1159/000481708
Novel Insights from Clinical Practice
Oxaliplatin-Induced Acute ST Segment Elevation Mimicking Myocardial Infarction: A Case Report
Subject Area:
Oncology
Kathrin Weidner; Michael Behnes; Jenny Haas; Jonas Rusnak; Paul Fuerner; Mathieu Kuska; Agnibh Mukherji; Martin Borggrefe; Ralf-Dieter Hofheinz; Ibrahim Akin
Oncol Res Treat (2018) 41 (1-2): 51–55.
https://doi.org/10.1159/000480661
Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 56–58.
https://doi.org/10.1159/000480017
Congress Report
PharmaForum
Metastasiertes Prostatakarzinom. Abirateronacetat jetzt noch breiter einsetzbar
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 60.
https://doi.org/10.1159/000486874
Lungen- und Urothelkarzinom. PD-L1-Blockade mit Atezolizumab: Überzeugend wirksam bei jedem PD-L1-Status
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 61–63.
https://doi.org/10.1159/000486875
Dosisdichte Chemotherapie beim Mammakarzinom. G-CSF-Prophylaxe sichert die Therapieerfolge
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 64.
https://doi.org/10.1159/000486876
Gastrointestinale Tumoren. Welches Potenzial hat die Immun-Checkpoint-Blockade bei fortgeschrittenen GI-Tumoren?
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 65–66.
https://doi.org/10.1159/000486877
Darzalex® beim Multiplen Myelom. Überragende Wirksamkeit beim ASH bestätigt
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 67–69.
https://doi.org/10.1159/000486878
PharmaNews
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 70–75.
https://doi.org/10.1159/000486879
Society Bulletins
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 76–82.
https://doi.org/10.1159/000486778
Meetings and Conferences
Subject Area:
Oncology
Oncol Res Treat (2018) 41 (1-2): 83–85.
https://doi.org/10.1159/000486808
